

References

Feverfew

- McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997. 12
- Awang DV. Parthenocide: demise of a facile theory of feverfew activity. *J Herbs Spices Med Plants* 1998;5:95-8. 49
- Murch SJ, Simmons CB, Saxena PK. Melatonin in feverfew and other medicinal plants. *Lancet* 1997;350:1598-9. [View abstract](#). 50
- Foster S. Feverfew, *Tanacetum parthenium*, botanical series #310. Austin, TX: Am Botanical Council, 1996. 724
- Kuritzky A, Elhacham Y, Yerushalmi Z, et al. Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. *Neurology* 1994;44(Suppl 2):A201. (Abstract 293P) 727
- McCrory DC, Matchar DB, Gray RN, et al. Evidence-based guidelines for migraine headache: overview of program description and methodology. US Headache Consortium, April 2000. Available at: www.aan.com/cgi-bin/whatsnewlink.pl?loc=/public/practiceguidelines. 5080
- Pittler MH, Vogler BK, Ernst E. Feverfew for preventing migraine. *Cochrane Database Syst Rev* 2000;3:CD002286. [View abstract](#). 6711
- Brun J, Claustrat B, Saddier P, Chazot G. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. *Cephalalgia* 1995;15:136-9. [View abstract](#). 6712
- Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. *J Pharm Pharmacol* 1988;40:743-5. [View abstract](#). 6713
- Patrick M, Heptinstall S, Doherty M. Feverfew in rheumatoid arthritis: a double-blind, placebo-controlled study. *Ann Rheum Dis* 1989;48:547-9. [View abstract](#). 6933
- Awang DVC. Prescribing therapeutic feverfew (*Tanacetum parthenium* (L.) Schultz Bip., syn. *Chrysanthemum parthenium* (L.) Bernh). *Int Med* 1998;1:11-3. 6935
- Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphhydryl groups. *J Pharm Pharmacol* 1987;39:459-65. [View abstract](#). 6936
- Wong HC. Is feverfew a pharmacologic agent? *CMAJ* 1999;160:21-2. [View abstract](#). 6937
- de Weerd GJ, Bootsman HPR, Hendriks H. Herbal medicines in migraine prevention. Randomized double-blind, placebo-controlled, crossover trial of a feverfew preparation. *Phytomedicine* 1996;3:225-30. 6938
- Sumner H, Salan U, Knight DW, Houlst JR. Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components. *Biochem Pharmacol* 1992;43:2313-20. [View abstract](#). 6939
- Williams CA, Houlst JR, Harborne JB, et al. A biologically active lipophilic flavonol from *Tanacetum parthenium*. *Phytochemistry* 1995;38:267-70. [View abstract](#). 6941
- 6942

- Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. *Lancet* 1985;1:1071-4. [View abstract](#). **6943**
- Makheja AN, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (*Tanacetum parthenium*). *Prostaglandins Leukot Med* 1982;8:653-60. [View abstract](#). **6944**
- Groenewegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. *J Pharm Pharmacol* 1990;42:553-7. [View abstract](#). **6945**
- Heptinstall S, Groenewegen WA, Spangenberg P, Losche W. Inhibition of platelet behaviour by feverfew: a mechanism of action involving sulphhydryl groups. *Folia Haematol Int Mag Klin Morphol Blutforsch* 1988;115:447-9. [View abstract](#). **6946**
- Williams CA, Harborne JB, Geiger H, Hoult JR. The flavonoids of *Tanacetum parthenium* and *T. vulgare* and their anti-inflammatory properties. *Phytochemistry* 1999;51:417-23. [View abstract](#). **6947**
- Jain NK, Kulkarni SK. Antinociceptive and anti-inflammatory effects of *Tanacetum parthenium* L. extract in mice and rats. *J Ethnopharmacol* 1999;68:251-9. [View abstract](#). **6948**
- Barsby R, Salan U, Knight DW, Hoult JR. Irreversible inhibition of vascular reactivity by feverfew. *Lancet* 1991;338:1015. [View abstract](#). **6950**
- Barsby RW, Salan U, Knight DW, Hoult JR. Feverfew extracts and parthenolide irreversibly inhibit vascular responses of the rabbit aorta. *J Pharm Pharmacol* 1992;44:737-40. [View abstract](#). **6951**
- Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. *Lancet* 1982;2:776. [View abstract](#). **6953**
- Makheja AN, Bailey JM. The active principle in feverfew. *Lancet* 1981;2:1054. [View abstract](#). **6954**
- Collier HO, Butt NM, McDonald-Gibson WJ, Saeed SA. Extract of feverfew inhibits prostaglandin biosynthesis. *Lancet* 1980;2:922-3. [View abstract](#). **6957**
- Ross JJ, Arnason JT, Birnboim HC. Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. *Planta Med* 1999;65:126-9. [View abstract](#). **6958**
- Lamminpaa A, Estlander T, Jolanki R, Kanerva L. Occupational allergic contact dermatitis caused by decorative plants. *Contact Dermatitis* 1996;34:330-5. [View abstract](#). **6959**
- Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. *Br Med J (Clin Res Ed)* 1985;291:569-73. [View abstract](#). **6960**
- Murphy JJ, Heptinstall S, Mitchell JR. Randomized, double-blind, placebo-controlled trial of feverfew in migraine prevention. *Lancet* 1988;2:189-92. [View abstract](#). **6961**
- Palevitch D, Earon G, Carasso R. Feverfew (*tanacetum parthenium*) as a prophylactic treatment for migraine- a double-blind, placebo-controlled study. *Phytotherapy Res* 1997;11:508-11. **6965**
- Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. *Cephalalgia* 1998;18:704-8. [View abstract](#). **12153**
- Pittler MH, Ernst E. Feverfew for preventing migraine. *Cochrane Database Syst Rev* 2004;(1):CD002286. [View abstract](#). **12383**

- Ernst E, Pittler MH. The efficacy and safety of feverfew (*Tanacetum parthenium* L.): an update of a systematic review. *Public Health Nutr* 2000;3:509-14. [View abstract](#). **12384**
- Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of *Tanacetum parthenium* (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study. *Cephalalgia* 2002;22:523-32. [View abstract](#). **12389**
- Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. *Headache* 2004;44:885-90. [View abstract](#). **12479**
- Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. *Rapid Commun Mass Spectrom* 2004;18:2273-81. [View abstract](#). **12483**
- Hwang D, Fischer NH, Jang BC, et al. Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. *Biochem Biophys Res Commun* 1996;226:810-8. [View abstract](#). **13239**
- Diener HC, Pfaffenrath V, Schnitker J, et al. Efficacy and safety of 6.25 mg t.i.d. feverfew CO₂-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study. *Cephalalgia* 2005;25:1031-41. [View abstract](#). **17963**
- Holland S, Silberstein SD, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology* 2012;78:1346-53. [View abstract](#). **19213**
- Sur R, Martin K, Liebel F, et al. Anti-inflammatory activity of parthenolide-depleted Feverfew (*Tanacetum parthenium*). *Inflammopharmacology*. 2009;17:42-9. [View abstract](#). **19357**
- Cady RK, Schreiber CP, Beach ME, et al. Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase. *Med Sci Monit*. 2005;11:165-69. [View abstract](#). **19358**
- Prusinski A, Durko A, and Niczyporuk-Turek A. [Feverfew as a prophylactic treatment of migraine]. *Neurol.Neurochir.Pol.* 1999;33 Suppl 5:89-95. [View abstract](#). **19359**
- Shrivastava R, Pechadre JC, and John GW. *Tanacetum parthenium* and *Salix alba* (Mig-RL) combination in migraine prophylaxis: a prospective, open-label study. *Clin Drug Investig.* 2006;26:287-96. [View abstract](#). **19361**
- Sil'vestrov VP, Kinitin AV, and Chesnokova, IV. [Immunological and metabolic disorders and the means for their correction in patients with chronic bronchitis]. *Ter.Arkh.* 1991;63:7-11. [View abstract](#). **22601**
- Saraceno R, Chiricozzi A, Nistico SP, et al. An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis. *J.Dermatolog.Treat.* 2010;21:363-66. [View abstract](#). **22602**
- Cady RK, Goldstein J, Nett R, et al. A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGestic M) in the treatment of migraine. *Headache* 2011;51:1078-86. [View abstract](#). **30868**
- Sun-Edelstein, C. and Mauskop, A. Foods and supplements in the management of migraine headaches. *Clin J Pain* 2009;25(5):446-452. [View abstract](#). **37534**

- Mauskop, A. Nonmedication, alternative, and complementary treatments for migraine. *Continuum (Minneapolis, Minn.)* 2012;18(4):796-806. [View abstract.](#) **39562**
- Christensen, L. P., Jakobsen, H. B., Paulsen, E., Hodal, L., and Andersen, K. E. Airborne Compositae dermatitis: monoterpenes and no parthenolide are released from flowering *Tanacetum parthenium* (feverfew) plants. *Arch Dermatol Res* 1999;291(7-8):425-431. [View abstract.](#) **42870**
- Gromek, D., Kisiel, W., Stojakowska, A., and Kohlmunzer, S. Attempts of chemical standardizing of *Chrysanthemum parthenium* as a prospective antimigraine drug. *Pol.J.Pharmacol.Pharm.* 1991;43(3):213-217. [View abstract.](#) **49916**
- Silberstein, S. D. Preventive treatment of headaches. *Curr Opin Neurol.* 2005;18(3):289-292. [View abstract.](#) **49919**
- Modi, S. and Lowder, D. M. Medications for migraine prophylaxis. *Am Fam.Physician* 1-1-2006;73(1):72-78. [View abstract.](#) **49928**
- Kemper, K. J. and Breuner, C. C. Complementary, holistic, and integrative medicine: headaches. *Pediatr.Rev.* 2010;31(2):e17-e23. [View abstract.](#) **49930**
- Czyz, M., Lesiak-Mieczkowska, K., Koprowska, K., Szulawska-Mroczek, A., and Wozniak, M. Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells. *Br.J.Pharmacol.* 2010;160(5):1144-1157. [View abstract.](#) **49931**
- Loder, E., Burch, R., and Rizzoli, P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. *Headache* 2012;52(6):930-945. [View abstract.](#) **49932**
- De Weerd, C. J., Bootsma, H. P., and Hendriks, H. Herbal medicines in migraine prevention Randomized double-blind placebo-controlled crossover trial of a feverfew preparation. *Phytomedicine.* 1996;3(3):225-230. [View abstract.](#) **49933**
- Hayes, N. A. and Foreman, J. C. The activity of compounds extracted from feverfew on histamine release from rat mast cells. *J Pharm Pharmacol* 1987;39(6):466-470. [View abstract.](#) **49943**
- Waller, P. C. and Ramsay, L. E. Efficacy of feverfew as prophylactic treatment of migraine. *Br Med J (Clin Res Ed)* 10-19-1985;291(6502):1128. [View abstract.](#) **49953**
- Pfaffenrath V, Fischer M, Friede M, and et al. Clinical dose-response study for the investigation of efficacy and tolerability of *Tanacetum parthenium* in migraine prophylaxis. *Deutscher Schmerzkongress; October 20-24, 1999, Munich, Germany.* 1999; **49956**
- Awang DV. Parthenocide: the demise of a facile theory of feverfew activity. *J Herbs Spices Med Plants* 1998;5(4):95-98. **49957**
- DeWeerd CJ, Bootsman H, and Hendricks H. Herbal medicines in migraine prevention. Randomized double-blind placebo-controlled crossover trial of a feverfew preparation. *Phytomed* 1996;3(3):225-230. **49958**
- Palevitch D, Earon G, and Carasso R. Feverfew (*Tanacetum parthenium*) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. *Phytother Res* 1997;11(7):508-511. **49959**
- Kuritzky A, Elhacham Y, Yerushalmi Z, and et al. Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. *Neurology* 1994;44(Suppl 2):A201. **90607**

Ferro EC, Biagini AP, da Silva ÍE, Silva ML, Silva JR. The combined effect of acupuncture and Tanacetum parthenium on quality of life in women with headache: randomised study. *Acupunct Med.* 2012 Dec;30(4):252-7. [View abstract](#).

90609

Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. *Cochrane Database Syst Rev.* 2015 Apr 20;4:CD002286. [Epub ahead of print][View abstract](#).

90886

Pareek A, Suthar M, Rathore G, Bansal V. Feverfew (*Tanacetum parthenium* L.): A systematic review. *Pharmacogn Rev.* 2011;5(9):103-110. [View abstract](#).